abstract |
The present invention provides cortexolone 17.alpha.-valerate for use in therapy, in particular for use as an antitumor active ingredient for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis as well as for use as an glucocorticoid modulator (in particular an antagonist). Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone 17.alpha.-valerate as active ingredient and at least one physiologically acceptable excipient for these same therpeutic uses. |